Viewing Study NCT03032991



Ignite Creation Date: 2024-05-06 @ 9:38 AM
Last Modification Date: 2024-10-26 @ 12:17 PM
Study NCT ID: NCT03032991
Status: UNKNOWN
Last Update Posted: 2017-01-26
First Post: 2017-01-13

Brief Title: Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
Sponsor: Universidad de Murcia
Organization: Universidad de Murcia

Study Overview

Official Title: Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers GD-BRAIN
Status: UNKNOWN
Status Verified Date: 2017-01
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GD-BRAIN
Brief Summary: The prospective multicenter study GD-Brain provides a better knowledge on the basis of neurological impairment in children born to mothers with gestational diabetes GDM GDM modifies placental structure and affect materno-fetal nutrient transfer Docosahexaenoic acid DHA play an important role on neurodevelopment and it is reduced in venous cord blood of newborns born to GDM In previous studies we have already demonstrated impaired DHA fetal levels not only using label fatty acids with stable isotopes administrated to pregnant women but also in observational studies in GDM as the prevention of obesity study PREOBE study in Granada and other similar study in Murcia The impaired cord DHA levels were associated to disturbed neurodevelopment in these children during the first year of life However it is uncertain the mechanisms underlying this impaired materno-fetal DHA transfer and implications for later life

The recent publication in Nature Journal of a selective transmembrane carrier for DHA in brain named major facilitator superfamily domain 2a MFSD2a open new expectations We detected disturbed MFSD2a levels in placentas from GDM which could be due to structural problems in this organ inflammation oxidation and metabolic changes related to diabetes might affect MFSD2a activity Moreover it is difficult to know whether disturbed MFSD2a levels in placenta may also indicate altered levels of this carrier in the brain from children born to GDM mothers which could contribute to neurodevelopment impairment in these subjects Recent studies also indicate that obesity alters the biosynthesis of eicosanoids derived from DHA with a decrease of protectins and resolvin of D-series which have powerful anti-inflammatory properties

The main aim of this study is to analyse potential differences on neurodevelopment and brain structure and functioning in children 8 years old born to GDM respect to those born to healthy normoweight mothers as well as to identify early biomarkers consistently related to neurodevelopment from early stages of life
Detailed Description: We will contact to participants from the PREOBE study and Murcias cohorts study to get involved a total of 174 children at 8 years of age The results from neurodevelopment evaluation by neuropsychological testing neurological functions rhythms and neuroimaging fMRI and DTI at 8 years old will be associated to clinical and metabolic data recorded during pregnancy

As secondary aim we would discern whether the decrease on DHA levels in offspring of GDM at birth is associated to disturbed neurodevelopment at 8 years old

The impact of maternal diabetes on placental MFSD2a and childrens resolvin and protectins derived from DHA will be measured in urine samples at 8 years old

Gut microbiota composition and function will be also studied to detect its role in the potential disturbances regarding the production of anti-inflammatory mediators

A part from the clinical study we will perform an intervention trial using animal models Gestational rats with diabetes and control rats will be treated with antioxidants and adipoRon in order to delay neuro-degeneration in these animals because of the diabetes as well as their influence on MFSD2a levels in placenta and brain All these studies may provide to the industry of valuable information to improve nutritional supplements during gestation or infancy to avoid potential delay of cognitive functions in offspring of diabetic mothers

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None